Loading...

Van Etten, Richard A

TitleProfessor
InstitutionUniversity of California, Irvine
DepartmentMedicine
Address1001 Health Sciences Road
Irvine CA 92697-3950
Phone(714) 456-8031
vCardDownload vCard

    Collapse Research 
    Collapse Research Activities and Funding
    Role of IKAROS in the Biology and Therapy of High-Risk Precursor B-Cell Leukemia
    NIH/NCI R01CA190964Dec 1, 2014 - Nov 30, 2019
    Role: Principal Investigator
    Novel Cellular Therapies for Ph+ leukemia
    NIH/NHLBI R01HL093981Sep 15, 2009 - Aug 31, 2012
    Role: Co-Principal Investigator
    Molecular Pathogenesis &Therapy of JAK2 V617F-induced Myeloproliferative Disease
    NIH/NHLBI R01HL089747Apr 1, 2008 - Mar 31, 2014
    Role: Principal Investigator
    Pathogenesis &Therapy of 8p11 Leukemia/Lymphoma
    NIH/NCI R01CA105043Apr 1, 2004 - Feb 28, 2010
    Role: Principal Investigator
    STUDIES OF BCR-ABL LEUKEMOGENESIS IN MICE
    NIH/NCI R01CA090576Apr 1, 2001 - Jul 31, 2022
    Role: Principal Investigator
    INHIBITOR OF THE C ABL TYROSINE KINASE
    NIH/NCI R01CA077691May 4, 1998 - Feb 28, 2005
    Role: Principal Investigator
    REGULATION AND FUNCTION OF C AB1 NUCLEAR TYROSINE KINASE
    NIH/NCI R01CA072465May 4, 1998 - Feb 28, 2003
    Role: Principal Investigator
    LEUKEMOGENESIS BY BCR/ABL GENES
    NIH/NCI R01CA057593Jul 1, 1995 - Jun 30, 1998
    Role: Principal Investigator
    Cancer Center Support Grant
    NIH/NCI P30CA062203Aug 15, 1994 - Jan 31, 2021
    Role: Principal Investigator
    Research Training in Oncology
    NIH/NCI T32CA009429Sep 1, 1981 - Jun 30, 2014
    Role: Co-Principal Investigator

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Mughal TI, Lion T, Abdel-Wahab O, Mesa R, Scherber RM, Perrotti D, Mauro M, Verstovsek S, Saglio G, Van Etten RA, Kralovics R. Precision immunotherapy, mutational landscape, and emerging tools to optimize clinical outcomes in patients with classical myeloproliferative neoplasms. Hematol Oncol. 2018 Aug 03. PMID: 30074634.
      View in: PubMed
    2. Mughal TI, Gotlib J, Mesa R, Koschmieder S, Khoury HJ, Cortes JE, Barbui T, Hehlmann R, Mauro M, Saussele S, Radich JP, Van Etten RA, Saglio G, Verstovek S, Gale RP, Abdel-Wahab O. Recent advances in the genomics and therapy of BCR/ABL1-positive and -negative chronic myeloproliferative neoplasms. Leuk Res. 2018 Apr; 67:67-74. PMID: 29466766.
      View in: PubMed
    3. Cortes J, Talpaz M, Smith HP, Snyder DS, Khoury J, Bhalla KN, Pinilla-Ibarz J, Larson R, Mitchell D, Wise SC, Rutkoski TJ, Smith BD, Flynn DL, Kantarjian HM, Rosen O, Van Etten RA. Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia. Haematologica. 2017 03; 102(3):519-528. PMID: 27927766.
      View in: PubMed
    4. Hu Y, Zhang Z, Kashiwagi M, Yoshida T, Joshi I, Jena N, Somasundaram R, Emmanuel AO, Sigvardsson M, Fitamant J, El-Bardeesy N, Gounari F, Van Etten RA, Georgopoulos K. Superenhancer reprogramming drives a B-cell-epithelial transition and high-risk leukemia. Genes Dev. 2016 09 01; 30(17):1971-90. PMID: 27664237.
      View in: PubMed
    5. Mughal TI, Abdel-Wahab O, Rampal R, Mesa R, Koschmieder S, Levine R, Hehlmann R, Saglio G, Barbui T, Van Etten RA. Contemporary insights into the pathogenesis and treatment of chronic myeloproliferative neoplasms. Leuk Lymphoma. 2016 07; 57(7):1517-26. PMID: 27240645.
      View in: PubMed
    6. Gu S, Chan WW, Mohi G, Rosenbaum J, Sayad A, Lu Z, Virtanen C, Li S, Neel BG, Van Etten RA. Distinct GAB2 signaling pathways are essential for myeloid and lymphoid transformation and leukemogenesis by BCR-ABL1. Blood. 2016 Apr 07; 127(14):1803-13. PMID: 26773044; PMCID: PMC4825414 [Available on 04/07/17].
    7. Tefferi A, Kantarjian H, Rajkumar SV, Baker LH, Abkowitz JL, Adamson JW, Advani RH, Allison J, Antman KH, Bast RC, Bennett JM, Benz EJ, Berliner N, Bertino J, Bhatia R, Bhatia S, Bhojwani D, Blanke CD, Bloomfield CD, Bosserman L, Broxmeyer HE, Byrd JC, Cabanillas F, Canellos GP, Chabner BA, Chanan-Khan A, Cheson B, Clarkson B, Cohn SL, Colon-Otero G, Cortes J, Coutre S, Cristofanilli M, Curran WJ, Daley GQ, DeAngelo DJ, Deeg HJ, Einhorn LH, Erba HP, Esteva FJ, Estey E, Fidler IJ, Foran J, Forman S, Freireich E, Fuchs C, George JN, Gertz MA, Giralt S, Golomb H, Greenberg P, Gutterman J, Handin RI, Hellman S, Hoff PM, Hoffman R, Hong WK, Horowitz M, Hortobagyi GN, Hudis C, Issa JP, Johnson BE, Kantoff PW, Kaushansky K, Khayat D, Khuri FR, Kipps TJ, Kripke M, Kyle RA, Larson RA, Lawrence TS, Levine R, Link MP, Lippman SM, Lonial S, Lyman GH, Markman M, Mendelsohn J, Meropol NJ, Messinger Y, Mulvey TM, O'Brien S, Perez-Soler R, Pollock R, Prchal J, Press O, Radich J, Rai K, Rosenberg SA, Rowe JM, Rugo H, Runowicz CD, Sandmaier BM, Saven A, Schafer AI, Schiffer C, Sekeres MA, Silver RT, Siu LL, Steensma DP, Stewart FM, Stock W, Stone R, Storb R, Strong LC, Tallman MS, Thompson M, Ueno NT, Van Etten RA, Vose JM, Wiernik PH, Winer EP, Younes A, Zelenetz AD, LeMaistre CA. In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc. 2015 Aug; 90(8):996-1000. PMID: 26211600.
      View in: PubMed
    8. Mughal TI, Barbui T, Abdel-Wahab O, Kralovics R, Jamieson C, Kvasnicka HM, Mullaly A, Rampal R, Mesa R, Kiladjian JJ, Deininger M, Prchal J, Hehlmann R, Saglio G, Van Etten RA. Novel insights into the biology and treatment of chronic myeloproliferative neoplasms. Leuk Lymphoma. 2015 Jul; 56(7):1938-48. PMID: 25330439.
      View in: PubMed
    9. Mughal TI, Vannucchi AM, Soverini S, Bazeos A, Tibes R, Saglio G, Abdel-Wahab O, Pardanani A, Hehlmann R, Barbui T, Van Etten R, Tefferi A, Goldman JM. Current pre-clinical and clinical advances in the BCR-ABL1-positive and -negative chronic myeloproliferative neoplasms. Haematologica. 2014 May; 99(5):797-801. PMID: 24790057; PMCID: PMC4008109.
    10. Mughal TI, Girnius S, Rosen ST, Kumar S, Wiestner A, Abdel-Wahab O, Kiladjian JJ, Wilson WH, Van Etten RA. Emerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignancies. Leuk Lymphoma. 2014 Sep; 55(9):1968-79. PMID: 24206094; PMCID: PMC4344832.
    11. Joshi I, Yoshida T, Jena N, Qi X, Zhang J, Van Etten RA, Georgopoulos K. Loss of Ikaros DNA-binding function confers integrin-dependent survival on pre-B cells and progression to acute lymphoblastic leukemia. Nat Immunol. 2014 Mar; 15(3):294-304. PMID: 24509510; PMCID: PMC4494688.
    12. Hsieh MY, Van Etten RA. IKK-dependent activation of NF-?B contributes to myeloid and lymphoid leukemogenesis by BCR-ABL1. Blood. 2014 Apr 10; 123(15):2401-11. PMID: 24464015; PMCID: PMC3983614.
    13. Krause DS, Lazarides K, Lewis JB, von Andrian UH, Van Etten RA. Selectins and their ligands are required for homing and engraftment of BCR-ABL1+ leukemic stem cells in the bone marrow niche. Blood. 2014 Feb 27; 123(9):1361-71. PMID: 24394666; PMCID: PMC3938148.
    14. Krause DS, Fulzele K, Catic A, Sun CC, Dombkowski D, Hurley MP, Lezeau S, Attar E, Wu JY, Lin HY, Divieti-Pajevic P, Hasserjian RP, Schipani E, Van Etten RA, Scadden DT. Differential regulation of myeloid leukemias by the bone marrow microenvironment. Nat Med. 2013 Nov; 19(11):1513-7. PMID: 24162813; PMCID: PMC3827980.
    15. Boissel L, Betancur-Boissel M, Lu W, Krause DS, Van Etten RA, Wels WS, Klingemann H. Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity. Oncoimmunology. 2013 Oct 01; 2(10):e26527. PMID: 24404423.
      View in: PubMed
    16. Ahmed W, Van Etten RA. Signal transduction in the chronic leukemias: implications for targeted therapies. Curr Hematol Malig Rep. 2013 Mar; 8(1):71-80. PMID: 23307472; PMCID: PMC3886724.
    17. Ahmed W, Van Etten RA. Alternative approaches to eradicating the malignant clone in chronic myeloid leukemia: tyrosine-kinase inhibitor combinations and beyond. Hematology Am Soc Hematol Educ Program. 2013; 2013:189-200. PMID: 24319181; PMCID: PMC4529996.
    18. Van Etten RA. New insights into the normal and leukemic stem cell niche: a timely review. Cytometry B Clin Cytom. 2013 Jan-Feb; 84(1):5-6. PMID: 23296593.
      View in: PubMed
    19. Van Etten RA, Mauro M, Radich JP, Goldman JM, Saglio G, Jamieson C, Soverini S, Gambacorti-Passerini C, Hehlmann R, Martinelli G, Perrotti D, Scadden DT, Skorski T, Tefferi A, Mughal TI. Advances in the biology and therapy of chronic myeloid leukemia: proceedings from the 6th Post-ASH International Chronic Myeloid Leukemia and Myeloproliferative Neoplasms Workshop. Leuk Lymphoma. 2013 Jun; 54(6):1151-8. PMID: 23121619; PMCID: PMC3612371.
    20. Klingemann H, Grodman C, Cutler E, Duque M, Kadidlo D, Klein AK, Sprague KA, Miller KB, Comenzo RL, Kewalramani T, Yu N, Van Etten RA, McKenna DH. Autologous stem cell transplant recipients tolerate haploidentical related-donor natural killer cell-enriched infusions. Transfusion. 2013 Feb; 53(2):412-8; quiz 411. PMID: 22738379; PMCID: PMC3549470.
    21. Abdel-Wahab O, Pardanani A, Bernard OA, Finazzi G, Crispino JD, Gisslinger H, Kralovics R, Odenike O, Bhalla K, Gupta V, Barosi G, Gotlib J, Guglielmelli P, Kiladjian JJ, Noel P, Cazzola M, Vannucchi AM, Hoffman R, Barbui T, Thiele J, Van Etten RA, Mughal T, Tefferi A. Unraveling the genetic underpinnings of myeloproliferative neoplasms and understanding their effect on disease course and response to therapy: proceedings from the 6th International Post-ASH Symposium. Am J Hematol. 2012 May; 87(5):562-8. PMID: 22460584; PMCID: PMC3491640.
    22. Gavrilescu LC, Molnár Á, Murray L, Garafalo S, Kehrl JH, Simon AR, Van Etten RA, Kyriakis JM. Retraction for Zhong et al. GCK is essential to systemic inflammation and pattern recognition receptor signaling to JNK and p38. Proc Natl Acad Sci U S A. 2012 Mar 27; 109(13):5134. PMID: 22411792; PMCID: PMC3323971.
    23. Walz C, Ahmed W, Lazarides K, Betancur M, Patel N, Hennighausen L, Zaleskas VM, Van Etten RA. Essential role for Stat5a/b in myeloproliferative neoplasms induced by BCR-ABL1 and JAK2(V617F) in mice. Blood. 2012 Apr 12; 119(15):3550-60. PMID: 22234689; PMCID: PMC3325042.
    24. O'Callaghan K, Lee L, Nguyen N, Hsieh MY, Kaneider NC, Klein AK, Sprague K, Van Etten RA, Kuliopulos A, Covic L. Targeting CXCR4 with cell-penetrating pepducins in lymphoma and lymphocytic leukemia. Blood. 2012 Feb 16; 119(7):1717-25. PMID: 22186993; PMCID: PMC3286348.
    25. Boissel L, Betancur M, Lu W, Wels WS, Marino T, Van Etten RA, Klingemann H. Comparison of mRNA and lentiviral based transfection of natural killer cells with chimeric antigen receptors recognizing lymphoid antigens. Leuk Lymphoma. 2012 May; 53(5):958-65. PMID: 22023526; PMCID: PMC3491067.
    26. Lu YF, Gavrilescu LC, Betancur M, Lazarides K, Klingemann H, Van Etten RA. Distinct graft-versus-leukemic stem cell effects of early or delayed donor leukocyte infusions in a mouse chronic myeloid leukemia model. Blood. 2012 Jan 05; 119(1):273-84. PMID: 22072555; PMCID: PMC3251232.
    27. Mughal TI, Radich JP, Van Etten RA, Quintás-Cardama A, Skorski T, Ravandi F, DeAngelo DJ, Gambacorti-Passerini C, Martinelli G, Tefferi A. Chronic myeloid leukemia 2011: successes, challenges, and strategies--proceedings of the 5th annual BCR-ABL1 positive and BCR-ABL1 negative myeloproliferative neoplasms workshop. Am J Hematol. 2011 Sep; 86(9):811-9. PMID: 21850662; PMCID: PMC3485684.
    28. Van Etten RA. BCL6: a novel target for therapy of Ph+ B cell acute lymphoblastic leukemia. Cancer Cell. 2011 Jul 12; 20(1):3-5. PMID: 21741592.
      View in: PubMed
    29. Hu MG, Deshpande A, Schlichting N, Hinds EA, Mao C, Dose M, Hu GF, Van Etten RA, Gounari F, Hinds PW. CDK6 kinase activity is required for thymocyte development. Blood. 2011 Jun 09; 117(23):6120-31. PMID: 21508411; PMCID: PMC3122937.
    30. Chan WW, Wise SC, Kaufman MD, Ahn YM, Ensinger CL, Haack T, Hood MM, Jones J, Lord JW, Lu WP, Miller D, Patt WC, Smith BD, Petillo PA, Rutkoski TJ, Telikepalli H, Vogeti L, Yao T, Chun L, Clark R, Evangelista P, Gavrilescu LC, Lazarides K, Zaleskas VM, Stewart LJ, Van Etten RA, Flynn DL. Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036. Cancer Cell. 2011 Apr 12; 19(4):556-68. PMID: 21481795; PMCID: PMC3077923.
    31. Okimoto RA, Van Etten RA. Navigating the road toward optimal initial therapy for chronic myeloid leukemia. Curr Opin Hematol. 2011 Mar; 18(2):89-97. PMID: 21252655; PMCID: PMC3496274.
    32. Van Etten RA, Koschmieder S, Delhommeau F, Perrotti D, Holyoake T, Pardanani A, Mesa R, Green T, Ibrahim AR, Mughal T, Gale RP, Goldman J. The Ph-positive and Ph-negative myeloproliferative neoplasms: some topical pre-clinical and clinical issues. Haematologica. 2011 Apr; 96(4):590-601. PMID: 21242185; PMCID: PMC3069237.
    33. Bellodi C, Lidonnici MR, Hamilton A, Helgason GV, Soliera AR, Ronchetti M, Galavotti S, Young KW, Selmi T, Yacobi R, Van Etten RA, Donato N, Hunter A, Dinsdale D, Tirrò E, Vigneri P, Nicotera P, Dyer MJ, Holyoake T, Salomoni P, Calabretta B. Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells. J Clin Invest. 2009 May; 119(5):1109-23. PMID: 19363292; PMCID: PMC2673867.
    34. Zhong J, Gavrilescu LC, Molnár A, Murray L, Garafalo S, Kehrl JH, Simon AR, Van Etten RA, Kyriakis JM. GCK is essential to systemic inflammation and pattern recognition receptor signaling to JNK and p38. Proc Natl Acad Sci U S A. 2009 Mar 17; 106(11):4372-7. PMID: 19246396; PMCID: PMC2657458.
    35. Gavrilescu LC, Van Etten RA. Murine retroviral bone marrow transplantation models for the study of human myeloproliferative disorders. Curr Protoc Pharmacol. 2008 Dec; Chapter 14:Unit14.10. PMID: 22294220.
      View in: PubMed
    36. Ko J, Patel N, Ikawa T, Kawamoto H, Frank O, Rivera RR, Van Etten RA, Murre C. Suppression of E-protein activity interferes with the development of BCR-ABL-mediated myeloproliferative disease. Proc Natl Acad Sci U S A. 2008 Sep 02; 105(35):12967-72. PMID: 18725623; PMCID: PMC2529058.
    37. Kisucka J, Chauhan AK, Patten IS, Yesilaltay A, Neumann C, Van Etten RA, Krieger M, Wagner DD. Peroxiredoxin1 prevents excessive endothelial activation and early atherosclerosis. Circ Res. 2008 Sep 12; 103(6):598-605. PMID: 18689572; PMCID: PMC4911701.
    38. Krause DS, Van Etten RA. Bedside to bench: interfering with leukemic stem cells. Nat Med. 2008 May; 14(5):494-5. PMID: 18463658; PMCID: PMC3490184.
    39. Gavrilescu LC, Van Etten RA. Production of replication-defective retrovirus by transient transfection of 293T cells. J Vis Exp. 2007; (10):550. PMID: 18989403; PMCID: PMC2557082.
    40. Krause DS, Van Etten RA. Right on target: eradicating leukemic stem cells. Trends Mol Med. 2007 Nov; 13(11):470-81. PMID: 17981087; PMCID: PMC4344828.
    41. Force T, Krause DS, Van Etten RA. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer. 2007 May; 7(5):332-44. PMID: 17457301.
      View in: PubMed
    42. Van Etten RA. Oncogenic signaling: new insights and controversies from chronic myeloid leukemia. J Exp Med. 2007 Mar 19; 204(3):461-5. PMID: 17353369; PMCID: PMC2137897.
    43. Giel-Moloney M, Krause DS, Chen G, Van Etten RA, Leiter AB. Ubiquitous and uniform in vivo fluorescence in ROSA26-EGFP BAC transgenic mice. Genesis. 2007 Feb; 45(2):83-9. PMID: 17269129; PMCID: PMC2121618.
    44. Zaleskas VM, Krause DS, Lazarides K, Patel N, Hu Y, Li S, Van Etten RA. Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F. PLoS One. 2006 Dec 20; 1:e18. PMID: 17183644; PMCID: PMC1762384.
    45. Krause DS, Lazarides K, von Andrian UH, Van Etten RA. Requirement for CD44 in homing and engraftment of BCR-ABL-expressing leukemic stem cells. Nat Med. 2006 Oct; 12(10):1175-80. PMID: 16998483.
      View in: PubMed
    46. Kerkelä R, Grazette L, Yacobi R, Iliescu C, Patten R, Beahm C, Walters B, Shevtsov S, Pesant S, Clubb FJ, Rosenzweig A, Salomon RN, Van Etten RA, Alroy J, Durand JB, Force T. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med. 2006 Aug; 12(8):908-16. PMID: 16862153.
      View in: PubMed
    47. Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N Engl J Med. 2005 Jul 14; 353(2):172-87. PMID: 16014887.
      View in: PubMed
    48. Derkinderen P, Scales TM, Hanger DP, Leung KY, Byers HL, Ward MA, Lenz C, Price C, Bird IN, Perera T, Kellie S, Williamson R, Noble W, Van Etten RA, Leroy K, Brion JP, Reynolds CH, Anderton BH. Tyrosine 394 is phosphorylated in Alzheimer's paired helical filament tau and in fetal tau with c-Abl as the candidate tyrosine kinase. J Neurosci. 2005 Jul 13; 25(28):6584-93. PMID: 16014719.
      View in: PubMed
    49. Shannon K, Van Etten RA. JAKing up hematopoietic proliferation. Cancer Cell. 2005 Apr; 7(4):291-3. PMID: 15837617.
      View in: PubMed
    50. Holdhoff M, Kreuzer KA, Appelt C, Scholz R, Na IK, Hildebrandt B, Riess H, Jordan A, Schmidt CA, Van Etten RA, Dörken B, le Coutre P. Imatinib mesylate radiosensitizes human glioblastoma cells through inhibition of platelet-derived growth factor receptor. Blood Cells Mol Dis. 2005 Mar-Apr; 34(2):181-5. PMID: 15727903.
      View in: PubMed
    51. Van Etten RA, Shannon KM. Focus on myeloproliferative diseases and myelodysplastic syndromes. Cancer Cell. 2004 Dec; 6(6):547-52. PMID: 15607959.
      View in: PubMed
    52. Krause DS, Van Etten RA. Adoptive immunotherapy of BCR-ABL-induced chronic myeloid leukemia-like myeloproliferative disease in a murine model. Blood. 2004 Dec 15; 104(13):4236-44. PMID: 15308567.
      View in: PubMed
    53. Million RP, Harakawa N, Roumiantsev S, Varticovski L, Van Etten RA. A direct binding site for Grb2 contributes to transformation and leukemogenesis by the Tel-Abl (ETV6-Abl) tyrosine kinase. Mol Cell Biol. 2004 Jun; 24(11):4685-95. PMID: 15143164; PMCID: PMC416425.
    54. Van Etten RA. Mechanisms of transformation by the BCR-ABL oncogene: new perspectives in the post-imatinib era. Leuk Res. 2004 May; 28 Suppl 1:S21-8. PMID: 15036938.
      View in: PubMed
    55. Hu Y, Liu Y, Pelletier S, Buchdunger E, Warmuth M, Fabbro D, Hallek M, Van Etten RA, Li S. Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. Nat Genet. 2004 May; 36(5):453-61. PMID: 15098032.
      View in: PubMed
    56. Roumiantsev S, Krause DS, Neumann CA, Dimitri CA, Asiedu F, Cross NC, Van Etten RA. Distinct stem cell myeloproliferative/T lymphoma syndromes induced by ZNF198-FGFR1 and BCR-FGFR1 fusion genes from 8p11 translocations. Cancer Cell. 2004 Mar; 5(3):287-98. PMID: 15050920.
      View in: PubMed
    57. Van Etten RA. c-Abl regulation: a tail of two lipids. Curr Biol. 2003 Aug 05; 13(15):R608-10. PMID: 12906815.
      View in: PubMed
    58. Neumann CA, Krause DS, Carman CV, Das S, Dubey DP, Abraham JL, Bronson RT, Fujiwara Y, Orkin SH, Van Etten RA. Essential role for the peroxiredoxin Prdx1 in erythrocyte antioxidant defence and tumour suppression. Nature. 2003 Jul 31; 424(6948):561-5. PMID: 12891360.
      View in: PubMed
    59. Smith KM, Yacobi R, Van Etten RA. Autoinhibition of Bcr-Abl through its SH3 domain. Mol Cell. 2003 Jul; 12(1):27-37. PMID: 12887890.
      View in: PubMed
    60. Van Etten RA. Studying the pathogenesis of BCR-ABL+ leukemia in mice. Oncogene. 2002 Dec 09; 21(56):8643-51. PMID: 12476310.
      View in: PubMed
    61. Roumiantsev S, Shah NP, Gorre ME, Nicoll J, Brasher BB, Sawyers CL, Van Etten RA. Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop. Proc Natl Acad Sci U S A. 2002 Aug 06; 99(16):10700-5. PMID: 12149456; PMCID: PMC125018.
    62. Goldberg Z, Vogt Sionov R, Berger M, Zwang Y, Perets R, Van Etten RA, Oren M, Taya Y, Haupt Y. Tyrosine phosphorylation of Mdm2 by c-Abl: implications for p53 regulation. EMBO J. 2002 Jul 15; 21(14):3715-27. PMID: 12110584; PMCID: PMC125401.
    63. Million RP, Aster J, Gilliland DG, Van Etten RA. The Tel-Abl (ETV6-Abl) tyrosine kinase, product of complex (9;12) translocations in human leukemia, induces distinct myeloproliferative disease in mice. Blood. 2002 Jun 15; 99(12):4568-77. PMID: 12036890.
      View in: PubMed
    64. Sattler M, Mohi MG, Pride YB, Quinnan LR, Malouf NA, Podar K, Gesbert F, Iwasaki H, Li S, Van Etten RA, Gu H, Griffin JD, Neel BG. Critical role for Gab2 in transformation by BCR/ABL. Cancer Cell. 2002 Jun; 1(5):479-92. PMID: 12124177.
      View in: PubMed
    65. Dash AB, Williams IR, Kutok JL, Tomasson MH, Anastasiadou E, Lindahl K, Li S, Van Etten RA, Borrow J, Housman D, Druker B, Gilliland DG. A murine model of CML blast crisis induced by cooperation between BCR/ABL and NUP98/HOXA9. Proc Natl Acad Sci U S A. 2002 May 28; 99(11):7622-7. PMID: 12032333; PMCID: PMC124303.